Clinical TrialsMonte Rosa plans to expand enrollment of their CRPC cohort to n=20-30 patients if a positive efficacy signal continues to be observed.
Financial PerformanceGLUE reported Q1 net income of $47MM and cash of $331MM (runway into 2028).
PartnershipsMonte Rosa's lead I&I asset, MRT-6160, is advancing toward multiple Phase 2 trials, supported through a partnership with Novartis.